Literature DB >> 15196692

Enhanced locomotor activity in rats with excitotoxic lesions of the entorhinal cortex, a neurodevelopmental animal model of schizophrenia: behavioral and in vivo microdialysis studies.

Tomiki Sumiyoshi1, Masahiko Tsunoda, Takashi Uehara, Kodai Tanaka, Hiroko Itoh, Chika Sumiyoshi, Masayoshi Kurachi.   

Abstract

In order to examine the construct validity of rats with excitotoxic damage of the left entorhinal cortex (EC) as an animal model of schizophrenia, we measured dopamine (DA)-related behaviors and methamphetamine (MAP)-induced DA release in the accumbens nucleus (NAC) in these animals. Quinolinic acid (lesion group) or phosphate buffer (sham group) was infused into the left EC of adolescent (postnatal 7 weeks) male Wistar rats. On the 14th and 28th postoperative day, spontaneous and MAP (1 mg/kg, i.p.)-induced locomotor activities, as well as MAP-induced stereotypy, were measured. The lesioned rats exhibited significantly greater spontaneous or MAP-induced locomotor activity on both of the postoperative days than did sham-operated animals, while EC lesions did not affect MAP-induced stereotypy on either occasion. MAP (1 mg/kg, i.p.)-induced DA release in NAC was measured by in vivo microdialysis on the 28th postoperative day. Lesioned rats did not show a significant change in MAP (1 mg/kg, i.p.)-induced DA release in NAC compared to sham-operated animals. These results suggest that excitotoxic damage of the left EC produces behavioral changes consistent with altered mesolimbic dopaminergic transmissions, possibly mediated by postsynaptic supersensitivity. Copyright 2004 Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196692     DOI: 10.1016/j.neulet.2004.04.027

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Psychopathological correlates of the entorhinal cortical shape in schizophrenia.

Authors:  C Christoph Schultz; Kathrin Koch; Gerd Wagner; Martin Roebel; Claudia Schachtzabel; Igor Nenadic; Carsten Albrecht; Jürgen R Reichenbach; Heinrich Sauer; Ralf G M Schlösser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11-07       Impact factor: 5.270

2.  Effects of neonatal excitotoxic lesions in ventral thalamus on social interaction in the rat.

Authors:  Rainer Wolf; Henrik Dobrowolny; Sven Nullmeier; Bernhard Bogerts; Herbert Schwegler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-30       Impact factor: 5.270

3.  The possible role of the kynurenine pathway in anhedonia in adolescents.

Authors:  Vilma Gabbay; Benjamin A Ely; James Babb; Leonard Liebes
Journal:  J Neural Transm (Vienna)       Date:  2011-07-24       Impact factor: 3.575

4.  Long-term effects of neonatal MK-801 treatment on prepulse inhibition in young adult rats.

Authors:  Takashi Uehara; Tomiki Sumiyoshi; Tomonori Seo; Hiroko Itoh; Tadasu Matsuoka; Michio Suzuki; Masayoshi Kurachi
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

5.  Developmental decrease of entorhinal-hippocampal communication in immune-challenged DISC1 knockdown mice.

Authors:  Xiaxia Xu; Lingzhen Song; Rebecca Kringel; Ileana L Hanganu-Opatz
Journal:  Nat Commun       Date:  2021-11-23       Impact factor: 14.919

6.  LORETA current source density for duration mismatch negativity and neuropsychological assessment in early schizophrenia.

Authors:  Tomohiro Miyanishi; Tomiki Sumiyoshi; Yuko Higuchi; Tomonori Seo; Michio Suzuki
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

7.  Dissociating effects of cocaine and d-amphetamine on dopamine and serotonin in the perirhinal, entorhinal, and prefrontal cortex of freely moving rats.

Authors:  M Pum; R J Carey; J P Huston; C P Müller
Journal:  Psychopharmacology (Berl)       Date:  2007-04-29       Impact factor: 4.415

Review 8.  Hemispheric differences in the mesostriatal dopaminergic system.

Authors:  Ilana Molochnikov; Dana Cohen
Journal:  Front Syst Neurosci       Date:  2014-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.